Novavax claims its covid vaccine is more than 90% effective

The experimental vaccine of the American company Novavax against covid is safe and has an efficacy of 90.4% against symptomatic infections, reaching 100% when it comes to avoiding severe or moderate cases, according to a statement released this Monday by signature.

The company, based in Maryland, ensures that the preparation is 93% effective against the main variants of the virus that circulate today and 91% in high-risk patients, such as people over 65 years of age.

NVX-CoV2373, the technical name for the recombinant nanoparticle-based vaccine, has met protection expectations in the last phase of clinical trials, which have included some 30,000 patients in the United States and Mexico.

The president and CEO of the company, Stanley Erck, has assured that "today Novavax is one step closer to being able to satisfy the crucial and persistent need of the global public health to have more vaccines against covid-19".

In Erck's opinion, "these clinical results confirm that NVX-CoV2373 is extremely effective and offers complete protection against moderate and severe COVID."

More information

• Moderna confirms its covid vaccine is effective against British and South African variants

• AstraZeneca's vaccine is 76% effective, based on updated data from its US trial

• Pfizer claims its coronavirus vaccine is 90% effective

The American company, a small company that has received support from the United States Government to develop the drug, intends to apply for regulatory authorizations in the third quarter of this year, once the final stages of the process, necessary to meet the requirements of regulatory agencies.

Novavax estimates that it could reach a manufacturing capacity of 100 million doses per month by the end of the third quarter of 2021 and 150 million doses per month by the end of the fourth quarter of this year.

Novavax President of Research and Development Gregory Glenn has stated that the data "shows consistent and high levels of efficacy and reaffirms the vaccine's ability to prevent COVID-19 amid the current genetic evolution of the virus."

The American company Novavax collaborates with the Spanish biopharmaceutical group Zendal - through its subsidiary Biofabri, based in O Porriño (Pontevedra) - for the industrial production of its vaccine in the European Union.

In the world there are a hundred experimental vaccines against covid in human trials, according to the registry of the World Health Organization.

The European Commission has already authorized four vaccines - those from the companies BioNTech / Pfizer, Moderna, AstraZeneca and Janssen - but other options have also been approved in other countries, such as the Russian Sputnik V and the Chinese ones from Sinovac, Sinopharm and CanSino.

In the Novavax trial, 20,000 participants were injected with two doses of the experimental vaccine, while the other 10,000 individuals received saline pricks for comparison.

In the vaccinated group, there were 14 symptomatic infections, all mild, while 63 cases were recorded in the control group, 10 of them moderate and four serious.

This is how 100% efficiency has been calculated against the most dangerous covid.

You can follow MATERIA on

Facebook

,

Twitter

and

Instagram

, or sign up here to receive

our weekly newsletter

.